Back to news

DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.

ACCESSWIRE•18/11/2026•06:00 ET
0

Key Highlights

  • ➤DataMEDS issues 630,000 shares to DiaGen, equal to 9.9% outstanding
  • ➤Partnership targets fifteen cytotoxic peptides for breast cancer validation
  • ➤Transaction value expected at $1.5 million through milestone contributions
  • ➤DataMEDS funds up to 50% of compute expenses under agreement
  • ➤DiaGen contributes wet-lab experiment cash as milestones are achieved

Expert Statements

Mohit Pandey, Chief AI Officer of DiaGen.ai

“Being able to access this robust primary tumor biobank and Helomics' proprietary capabilities to identify new therapeutic targets and leverage our proprietary BLACKCOMB artificial intelligence chemical drug discovery platform to design the best candidates for human clinical development is a transformative opportunity for DiaGen”

Mohit Pandey, Chief AI Officer of DiaGen.ai

“Building upon the foundational methodologies in my recent peer-reviewed research in Nature Communications, we know that the only way for artificial intelligence companies in the biotechnology space to truly differentiate themselves is to train their models on unique, high-dimensional biological data in areas of high unmet medical need.”

Mohit Pandey, Chief AI Officer of DiaGen.ai

“With this agreement, DiaGen is gaining access to an untapped resource of real-world tumor data upon which to build a novel intellectual property portfolio together with Helomics.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“We are excited to have identified our first partner that begins the process of monetizing the unique resources in our lab and will help us unlock the tremendous value resident in one of the world's largest curated biobanks while also allowing us to participate in the long-term value creation of biotechnology drug discovery”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“Helomics is also now open to establish new practicing oncologist relationships for its commercially available ChemoFx® Assay, as well as re-activate historical relationships, which will help us continue to grow the size and diversity of the Helomics Biobank.”

Gerald Commissiong, Interim Co-CEO of DataMEDS

“Partnering with DiaGen lets us contribute to the creation of groundbreaking new therapies that can improve the standard of care for patients with cancer while allowing us to participate in the value of the new intellectual property created leveraging our unique resources.”

TAMPA, FL AND VANCOUVER, BC / ACCESS Newswire / November 18, 2026 / DataMeds AI, Inc. ("DataMeds SI," "DataMEDS" or the "Company") (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that its wholly-owned subsidiary Helomics, Inc. (Helomics), a CLIA-certified cancer diagnostics laboratory, has entered into a cancer target discovery and drug candidate optimization partnership with DiaGen.ai, an award-winning, AI-driven drug discovery company based in Vancouver, Canada.

Helomics maintains one of the world's largest repositories of primary tumor specimens (the "Helomics Biobank") with over 70,000 tumor biopsies, including more than 50,000 gynecologic cancer samples, amassed over nearly three decades. Helomics has also developed proprietary cell painting and patient-tumor derived 3D spheroids that represent a test matrix that preserves tumor stroma and correlates to its 2D platform with associated drug response data (commercially available, insurance reimbursed ChemoFx® Assay chemotherapy selection laboratory developed test), allowing for a unique high throughput testing approach. By introducing tumor heterogeneity at pre-clinical stages leveraging primary tumor features, Helomics hopes to inform better drug response predictions to enable the selection of drug/tumor combinations and increase the probability of clinical success.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in